GleamWall
中文EN

OSTX OS Therapies Inc

Pharmaceutical Preparations · NYSE · SEC CIK 1795091 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-139.4%
TTM EPS YoY9.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-513.1%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets296.1%
Debt / equity—
Current ratio0.08x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.42x
Accruals ratio-296.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$5.97M$6.07M$7.35M$8.80M$3.76M$2.50M$1.31M$870,469
SG&A expense$3.06M$2.50M$2.82M$3.19M$3.12M$2.34M$3.69M$2.10M
Operating income-$9.03M-$8.58M-$10.17M-$11.99M-$6.88M-$4.84M-$5.00M-$2.97M
Interest expense$621,298$5,581$75,344————$7,556
Net income-$11.28M-$8.63M-$10.40M-$13.46M-$6.88M-$4.54M-$3.88M-$2.99M
EBITDA-$8.91M-$8.45M-$10.04M-$11.86M-$6.75M-$4.73M-$5.00M-$2.97M
EPS (basic)-0.23-0.20-0.27—-0.22-0.19-0.18—
EPS (diluted)-0.23-0.20-0.27—-0.22-0.19-0.18—
Weighted avg. shares (diluted)48.06M43.90M38.67M—31.96M25.11M21.25M—
Banking
Deposits————$400,000——$150,000
Balance sheet
Cash & equivalents$431,816$205,035$917,552$269,830$1.88M$2.80M$2.97M$5.53M
Current assets$1.98M$3.64M$917,552$332,912$2.32M$3.55M$4.10M$5.53M
PP&E, net$405$1,100$1,795$2,490$3,185$3,880$4,575$5,270
Intangibles$6.13M$6.26M$6.38M$6.50M$6.86M$6.86M——
Total assets$8.11M$9.90M$7.30M$6.84M$8.95M$10.31M$4.25M$5.54M
Current liabilities$23.91M$20.64M$16.95M$11.76M$4.15M$3.46M$3.54M$4.63M
Total liabilities$24.01M$20.74M$17.05M$11.86M$4.25M$3.56M$3.64M$4.73M
Shareholders' equity-$16.97M-$11.91M-$10.82M-$6.10M$3.64M$4.94M-$4.19M-$3.27M
Shares outstanding47.07M45.28M39.28M37.11M33.27M29.66M21.35M20.87M
Cash flow statement
Operating cash flow-$4.65M-$5.53M-$4.56M-$3.73M-$4.71M-$2.36M-$3.44M-$2.37M
Capital expenditure———$0$0$316,423$150,000—
Free cash flow———-$3.73M-$4.71M-$2.68M-$3.59M—
Investing cash flow———$0$0-$292,787-$173,636—
Financing cash flow$4.88M$4.82M$5.21M$2.12M$3.78M$2.48M$1.05M$6.05M
Depreciation & amortization$124,938$124,938$124,938$124,938$124,938$112,514$695$1,390
Stock-based compensation$2.04M$1.33M$1.44M$1.60M$814,932$905,182$941,283$268,300

Free plan shows the latest 8 periods; Pro shows all 15 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.